AiCure and Defense Health Agency to Develop Targeted PTSD Treatment for Service Members and Veterans


AiCure announced the DHA PTSD-DT Program will deploy AiCure's AI platform in its post-traumatic stress disorder (PTSD) adaptive platform trial (APT) to simultaneously evaluate the efficacy of multiple PTSD treatments in both active service members and veterans.

AiCure will work with the DHA PTSD-DT Program to deploy its medication adherence platform to guide patients in their compliance to complex treatment regimens, as well as its digital biomarker solution to unobtrusively capture the subtleties of a patient's response.

Read more about the program here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.